deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01857115

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (wCCyd)

A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS

Sponsor: European Myeloma Network B.V.

Conditions Multiple Myeloma
Interventions Carfilzomib Cyclophosphamide Dexamethasone
Updated 15 times since 2017 Last updated: Nov 11, 2024 Started: Apr 30, 2013 Primary completion: Nov 30, 2013 Completion: Sep 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by European Myeloma Network B.V. and has accumulated 15 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Sep 2020 · 24 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Mar 2024 · 12 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – present · 21 months · monthly snapshot

Change History

15 versions recorded

  1. Dec 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Nov 2024 — Dec 2024 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Mar 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Apr 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Unknown Status → Active Not Recruiting

  5. Feb 2021 — Mar 2021 [monthly]

    Unknown Status PHASE1_PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Unknown Status PHASE1_PHASE2

  7. Sep 2020 — Jan 2021 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

  8. Sep 2018 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jan 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Myeloma Network B.V.
  • Fondazione EMN Italy Onlus
Data source: European Myeloma Network B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations